FDA says Zicam enforcement routine
This article was originally published in The Tan Sheet
Executive Summary
FDA says simultaneously announcing a consumer safety alert and sending a warning letter to Matrixx Initiatives about the risks of Zicam zinc-containing intranasal homeopathic products due to potential loss of smell is not an unusual action, as some industry stakeholders suggest. Center for Drug Evaluation and Research officials say "warning letters are issued to achieve voluntary compliance," such as the agency's June 16 communication with Matrixx about Zicam. "When it is consistent with the public protection responsibilities of the agency and depending on the nature of the violation, it is FDA's practice to give firms an opportunity to take voluntary and prompt corrective actions before it initiates an enforcement action," CDER said July 13. Matrixx voluntarily recalled the products the same day it received the warning letter (1"The Tan Sheet" June 29, 2009)
You may also be interested in...
FDA Uses "Unusual" Action To Get Matrixx's Zicam Off The Market
In a rare action, FDA simultaneously alerted consumers not to use Matrixx Initiatives' intranasal Zicam products because of potential safety problems and warned Matrixx to remove the products from market without first consulting with the firm
Empowered By Evidence Debuts Lists Of Natural Health Ingredients Meeting Its Standards
Global nonprofit supporting evidence-based product development in natural health sector and American Botanical Council announce database intended to help consumers, researchers and health care professionals make natural product choices based on specific scientific and clinical evidence.
Getting A Jump On MoCRA Compliance; Due Diligence Now Will Lighten Load, Risks Later
Cosmetics companies should not sit idly waiting for FDA to clarify new requirements under the Modernization of Cosmetic Regulations Act, speakers agreed at the Independent Beauty Association’s 2023 Technical/Regulatory Forum. Companies should be reviewing products, people and processes, including those of contract manufacturers, to get ahead of the curve.